AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01124916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted laparoscopic abdominal sacrocolpopexy
Description: Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
Study NCT01124916 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic abdominal sacrocolpopexy
Description: Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
Study NCT02010021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
Study NCT02361983 — intervention group
Intervention type: DEVICE
Intervention: DLT versus bronchial blockers
Description: Safety and efficacy of the double-lumen tubes (DLT) and bronchial blockers (BB) for lung isolation in patients undergoing thoracic surgery have been extensively studied and most of the results show similar rates of successful placement and lung collapse. DLT and BB are more frequently inserted by anesthetists who are expert in thoracic anesthesia, with dedicated but different training.
Study NCT00765921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
Study NCT01864525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive capsule
Study NCT06312501 — intervention group
Intervention type: DEVICE
Intervention: Satelia®Cardio
Description: Use of a remote patient monitoring system by NP Medical.
Study NCT06312501 — intervention group
Intervention type: OTHER
Intervention: Conventional care
Description: No use of RPM solutions for follow-up
Study NCT01714414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FZD
Study NCT03591744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT03591744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03591744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV and PO
Study NCT03591744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT03591744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT03461315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional assistance model
Description: Preventive home visits carried out by a Team Dedicated Exclusively to the Home Patient.
Study NCT02020785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher phosphorus period
Description: Commercially-available unaltered food/beverage products containing phosphorus additives (\~1gm/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives.
Study NCT02020785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lower phosphorus period
Description: Commercially-available unaltered food/beverage products without phosphorus additives (\<10mg/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives.
Study NCT01077531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Otelixizumab
Description: Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
Study NCT01077531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo for intravenous infusion
Study NCT00294632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting Dose 10 mg By Mouth Daily on Days 1-21
Study NCT00294632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 By Vein Weekly for 4 Weeks
Study NCT03208283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Water method group
Description: During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
Study NCT03208283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation group
Description: During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to at least 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
Study NCT00344305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine live, intranasal
Description: A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains.
Study NCT02747251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthen your Shoulder
Description: A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.
Study NCT02747251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder.
Study NCT02747251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder.
Study NCT04264663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Furazolidone-tetracycline-containing quadruple regimens
Study NCT04264663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole
Description: tinidazole-tetracycline-containing quadruple regimens
Study NCT02036827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.
Study NCT03358342 — intervention group
Intervention type: OTHER
Intervention: ePneumonia CDS
Description: ePneumonia clinical decision support system for community-onset pneumonia
Study NCT03732729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: massage chair
Description: Patient should use massage chair, twice per day, for 30minutes